6838
台新藥
-0.30 (-1.26%)23.6090成交張數–本益比2.60股價淨值比0.00%殖利率2026-09-11資料日期
每股盈餘
柱為單季 EPS,線為近四季合計;近十年
| 季度 | 單季 EPS | 年增 | 近四季 EPS | 歸屬母公司淨利(億) | 淨利率 | ROE(季) | ROE(近四季) |
|---|---|---|---|---|---|---|---|
| 2026Q2 | -0.45 | -204.7% | -1.26 | -0.68 | -2235.1% | -4.81% | -12.93% |
| 2026Q1 | -0.10 | – | -0.38 | -0.15 | -33.6% | -1.05% | -3.94% |
| 2025Q4 | -0.31 | – | -0.55 | -0.48 | -1486.8% | -3.23% | -5.56% |
| 2025Q3 | -0.40 | – | -0.51 | -0.59 | -6497.5% | -3.85% | -4.77% |
| 2025Q2 | 0.43 | – | – | 0.64 | 1350.5% | 4.18% | – |
| 2025Q1 | -0.27 | – | – | -0.41 | -6859.4% | -2.67% | – |
| 2024Q4 | -0.27 | – | – | -0.39 | -655.6% | -2.45% | – |
| 2024Q3 | -0.29 | – | – | -0.46 | -1062.7% | – | – |